Arterial hypertension frequently occurs in association with myocardial ischaemia and is an independent and significant risk factor for the development of coronary artery disease (CAD), as is left ventricular hypertrophy due to arterial hypertension. The prevalence of CAD in patients with hypertension is high, while hypertension occurs in approximately 60% of patients with CAD. Myocardial ischaemia occurs both in the presence and absence of CAD, probably as the result of limitation of coronary vasodilator capacity and reduction in coronary flow. This may occur in hypertension due to increased transmural coronary artery resistance, alterations in the vascular wall and endothelial dysfunction. Furthermore, left ventricular hypertrophy itself predisposes the heart towards ischaemia due to an increased diffusion distance between capillaries.
Introduction
Arterial hypertension frequently occurs in association with myocardial ischaemia and is an independent and significant risk factor for the development of coronary artery disease (CAD). The most impressive data to support this observation have been provided by the Framingham Study [l~31 , which demonstrated that left ventricular hypertrophy due to arterial hypertension represented a significant cardiovascular risk factor for the development of CAD, sudden cardiac death and congestive heart failure ( Table 1) .
The prevalence of CAD in patients with arterial hypertension is high, depending on the duration and severity of the blood pressure elevation' 3 " 81 . Furthermore, if other risk factors, such as hypercholesterolaemia, diabetes mellitus, cigarette smoking or family history, are present, then the probability of developing CAD increases with each additional risk factor.
Similarly, the prevalence of hypertension in patients with CAD is high. Indeed, in a general population of patients with angina pectoris, the incidence of arterial hypertension lies in the vicinity of 60% [9] .
Myocardial ischaemia and hypertension
Myocardial ischaemia associated with arterial hypertension does not only occur in the presence of coronary artery stenoses. All manifestations of myocardial ischaemia, such as angina pectoris, asymptomatic ischaemia, ischaemic ventricular arrhythmias and sudden cardiac death, can also be seen in hypertensive patients without demonstrable CAD. Although the mechanisms are not fully understood, the regulation of blood flow in the coronary circulation is of utmost importance since, even at rest, the myocardium utilizes all the oxygen available. Therefore, increased oxygen demand, for example during exercise, can only be met by increases in coronary flow. Thus, any limitations of coronary vasodilator capacity will limit coronary flow reserve and thereby set the stage for the occurrence of myocardial ischaemia. Such limitations may occur in hypertension as a result of increased transmural coronary artery resistance, which limits coronary flow capacity, and by alterations in the structure of the vascular wall, which may limit coronary vasodilator capacity. In addition, endothelial dysfunction may also be present, leading to further limitation of vasodilator capacity. Furthermore, in hypertensive patients, myocardial oxygen consumption may already be elevated during increased pressure work and when sympathetic tone is increased.
Finally, left ventricular hypertrophy in itself predisposes the heart towards the development of ischaemia, due to increased diffusion distances for oxygen and metabolites. This can be related to increased fibre thickness, even if the number of capillaries is maintained. Each myocardial fibre is surrounded by four capillaries and this relationship only changes if excessive hypertrophy occurs, with a heart weight of >500g (critical heart weight). Furthermore, left ventricular hypertrophy is also a risk factor for cardiac events ( Table 2) .
The incidence and significance of myocardial ischaemia in hypertension has been investigated extensively. Hedblad and Janzon [l0) studied 341 men with no history of ischaemic heart disease and evaluated the relationship between hypertension and asymptomatic ischaemic ST-segment depression on one hand and cardiovascular morbidity and mortality on the other. Overall, 23% of their patients exhibited one or more episodes of silent myocardial ischaemia. In normotensive men the incidence of ischaemic ST depression was only 19%, while in hypertensive men it was 28%. The highest incidence of episodes of ischaemic ST-segment depression (41%) was observed in treated hypertensive men with inadequate blood pressure control, who also had a higher event rate (14%) than that seen in the total male hypertensive population. The highest rate of cardiovascular complications was observed in patients who suffered both inadequate blood pressure control and aysmptomatic ST-segment depression.
In a further study, 150 hypertensive patients (96 men and 54 women, aged 56 ± 9 years) were assessed 18 '" 1 (Table 3) . Transient myocardial ischaemia was seen in 30% of these patients (Table 4) , with 92% of these episodes being asymptomatic. It should also be noted that in the presence of a positive Sokolow-Lyon index (indicating left ventricular hypertrophy) the presence of ischaemic ST-segment depression is increased remarkably. Moreover, in 13 of 14 patients, ST-segment depression was reproducible after 4 weeks of placebo treatment (Table 4) . Data from this study were also used to correlate Furthermore, the literature amply documents that the incidence of non-fatal myocardial infarction and of left ventricular hypertrophy is a risk factor in itself cardiac death during follow-up to blood pressure, the for the development of arrhythmia, even without presence of left ventricular hypertrophy (as indicated by hypokalaemia, in hypertension (Table 6 ). a positive Sokolow-Lyon index), the occurrence of ventricular premature beats and the incidence of STsegment depression. Table 5 demonstrates ST-segment ThG TOl© Of Calcium antagonists depression or ST-segment depression associated with ventricular premature beats as the most predictive prog-The application of calcium antagonists in patients with nostic parameters. Indeed, Cox regression analysis has hypertension can be considered one of the major adshown that the relative risk of developing cardiovascular vances in cardiovascular therapy. However, in the conevents in hypertensive heart disease was highest in text of this article, two questions need to be answered: patients with transient ischaemic episodes, especially (1) what does this group of drugs offer in terms of if left ventricular hypertrophy was present (Table 4) . pharmacodynamics in patients with hypertension and myocardial ischaemia, with or without CAD; (2) do these drugs exert beneficial effects over and above correction of hypertension?
There is insufficient space to allow extensive quotation of the vast literature on calcium antagonist drugs, which have been reviewed in the publications of Fleckenstein' 181 and Opie [191 . However, in general, calcium antagonist drugs lower blood pressure due to arteriolar vasodilation and, with some, negative inotropic effects on the myocardium. A few calcium antagonists also lower heart rate. Vasodilation is affected through relaxation of arteriolar smooth muscle, especially at the level of the resistance vessels. The effect, however, is non-specific and is most pronounced wherever more vascular smooth muscle is present. As a result, parenchymal blood flow increases and, in the case of the myocardium, so does coronary flow.
As a consequence, effective treatment of hypertension with calcium antagonists is associated with a regression of left ventricular hypertrophy. Furthermore, independent of regression of hypertrophy, calcium antagonists seem to improve diastolic function by increasing the rate of diastolic relaxation. It has also been observed that these agents can attenuate the damage caused by reperfusion of cardiac tissue'
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. This effect has also been observed in other organs affected by hypertension, for example in the kidneys.
However, of greatest interest is the vasoprotective effect of calcium antagonists, which has been well demonstrated experimentally' . It seems that such vascular protection can prevent the development of arteriosclerosis in hypertensive animals when calcium antagonist drugs are given early. Even if arteriosclerosis is already present, then a slowing of the natural progression of the disease and, in some instances, regression, can be seen.
For example, long-term treatment of spontaneously hypertensive rats over 19-21 months, beginning at the age of 4 weeks until death, provided almost complete protection from arteriosclerosis. At doses of nifedipine, nitrendipine, nisoldipine, nimodipine and verapamil which normalize blood pressure, the life expectancy of the rats is increased and no arteriosclerosis develops. Conversely, if dihydralazine is given at a dose which normalizes blood pressure then the life expectancy of the rats is shortened and, in spite of pressure normalization, arteriosclerosis develops' 2 ' 1 .
Similarly, long-term treatment of salt-sensitive Dahl rats (Dahl S) over 12 months, beginning at age 6 weeks until death, with high doses of nitrendipine, amlodipine and anipamil, normalizes blood pressure, prolongs life expectancy four-fold and completely protects against the development of arteriosclerosis. If nitrendipine is given in a lower dose, which neither normalizes nor even significantly lowers blood pressure, life expectancy is prolonged and arteriosclerosis develops in a delayed and reduced manner' 221 .
From these experiments Fleckenstein and coworkers' 518 ' 21 " 23 ' concluded that treatment with calcium antagonists results in a pronounced vasoprotective effect through normalization of blood pressure and the effect of the calcium antagonist on the vascular wall itself.
Therefore, calcium antagonists are considered to be of great value in arterial hypertension. However, their vasoprotective effect, and in particular their retardation of arteriosclerosis or inhibition of the occurrence of new arteriosclerotic lesions, has not so far been convincingly demonstrated in man' 25 '. Only a mild reduction in the appearance of new atherosclerotic lesions could be observed in established coronary atherosclerosis by calcium antagonist treatment with nifedipine or nicardipine' 26271 . Comparison of the experimental animal data with the human situation indicates that the main difference appears to be the point in time at which calcium antagonist treatment begins. In the hypertensive animal treatment has been instituted early, whereas in man treatment usually begins when arteriosclerotic complications are present. It therefore remains to be demonstrated that early, effective anti-hypertensive treatment protects the patient from the development of arteriosclerosis, CAD and left ventricular hypertrophy, together with its well-known sequelae and association with serious cardiovascular events.
